BXP, Inc. (BXP)

NYSE Real Estate Office REITs S&P 500
$65.01
-0.23 (-0.35%)
Close of Nov 06, 2026 · end-of-day data

BXP 8-K filings in 2025

Every material Form 8-K BXP filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs in 2025815 on record in all
Latest filing in 2025Dec 22, 2025leadership
High impact (4-5)3of 8 briefs
TonePositive1Mixed3Neutral4
earnings 4financing 3leadership 1
Dec 22, 5:17 PM ET

BXP extends CEO Owen Thomas's employment agreement through December 31, 2029

Neutral leadership Written later 5.027.01

BXP amended and restated the employment agreement of CEO and Chairman Owen D. Thomas, extending his term through December 31, 2029, from a previous expiration in December 2026. The company also granted equity awards under a 2025 Outperformance Plan to Mr. Thomas and other senior leaders, which vest only if BXP's dividend-adjusted stock price reaches set levels, and it expects about $11.6 million of related expense in 2026.

  • Term runs from December 22, 2025 through December 31, 2029; base salary stays at $950,000 and target bonus is $2,350,000
  • Outperformance Plan grants could total up to 711,864 LTIP Units; Mr. Thomas's grant is 211,864 units at maximum
  • Awards require a dividend-adjusted stock price of at least $90.00 for 20 consecutive trading days to earn any units; maximum requires $118.00
  • BXP expects about $32.1 million of OPP compensation expense over four years, including about $11.6 million, or $0.07 per share, in 2026
Read the filing on SEC.gov ↗
Oct 28, 4:22 PM ET

BXP swings to $121.7 million Q3 net loss on impairment charges

Mixed earnings Written later 2.02

BXP reported third-quarter 2025 results showing a net loss attributable to BXP of $121.7 million, or $0.77 per diluted share, compared with net income of $89.0 million, or $0.56 per share, in the prior quarter. Revenue rose slightly to $871.5 million and diluted FFO per share increased to $1.74 from $1.71, but the loss reflects a non-cash impairment charge of approximately $145.1 million tied to unconsolidated joint ventures and $68.9 million of impairment losses on pending dispositions.

  • Net loss attributable to BXP of $121.7 million, or $0.77 per diluted share, for the quarter ended September 30, 2025, versus net income of $89.0 million, or $0.56 per share, for the quarter ended June 30, 2025
  • Total revenue of $871.5 million, up from $868.5 million in the prior quarter; diluted FFO per share of $1.74, up from $1.71
  • Non-cash impairment charge of approximately $145.1 million in loss from unconsolidated joint ventures, plus $68.9 million of impairment losses related to pending dispositions
  • Full-year 2025 guidance projects diluted EPS of $0.99 to $1.02 and diluted FFO per share of $6.89 to $6.92; quarterly dividend was $0.70 per share versus $0.98 in the prior quarter
Read the filing on SEC.gov ↗
Sep 29, 4:37 PM ET

BXP's operating partnership completes $1.0 billion exchangeable senior notes sale due 2030

Neutral financing Written later 1.012.033.028.01

On September 29, 2025, BXP's operating partnership, Boston Properties Limited Partnership, completed the sale of $1.0 billion of 2.00% exchangeable senior notes due October 1, 2030, including the full exercise of the initial purchasers' option for an additional $150 million. The notes can be exchanged into BXP common stock at an initial price of about $92.44 per share, which means dilution is possible if holders exchange and the partnership elects to settle in shares. The company said in its September 24 and 25 announcements that proceeds would largely be used to fund repayment of $1.0 billion of 3.650% senior notes maturing February 1, 2026.

  • Aggregate principal of $1.0 billion, including a $150 million option exercised in full, with a 2.00% annual interest rate payable April 1 and October 1 beginning April 1, 2026
  • Initial exchange price of approximately $92.44 per share, a premium of about 22.5% over the $75.46 last reported sale price on September 24, 2025
  • Pricing announcement stated estimated net proceeds of about $975.2 million if the option was exercised in full, with about $29.8 million used for capped call transactions
  • Notes are structurally subordinated to all existing and future liabilities of the partnership's subsidiaries and must be repaid or redeemed at maturity unless exchanged or repurchased
Read the filing on SEC.gov ↗
Jul 29, 5:37 PM ET

BXP Q2 2025 net income rises to $89.0 million, or $0.56 per diluted share

Positive earnings Written later 2.02

BXP, Inc. reported second-quarter 2025 results, with net income attributable to BXP of $89.0 million, or $0.56 per diluted share, up from $61.2 million, or $0.39 per share, in the first quarter of 2025. Diluted FFO per share rose to $1.71 from $1.64, and the company set 2025 full-year diluted EPS guidance of $1.74 to $1.82 and third-quarter EPS guidance of $0.41 to $0.43.

  • Revenue was $868.5 million for Q2 2025, compared with $865.2 million in Q1 2025.
  • Diluted FFO per share was $1.71 for Q2 2025, compared with $1.64 in Q1 2025.
  • Full-year 2025 guidance: diluted EPS of $1.74 to $1.82 and diluted FFO per share of $6.84 to $6.92.
  • Third-quarter 2025 guidance: diluted EPS of $0.41 to $0.43 and diluted FFO per share of $1.69 to $1.71.
Read the filing on SEC.gov ↗
Apr 29, 4:18 PM ET

BXP posts Q1 2025 EPS of $0.39 and FFO of $1.64 per share, down from $1.79

Mixed earnings Written later 2.02

BXP, Inc. reported first-quarter 2025 net income attributable to BXP of $61.2 million, or $0.39 per diluted share, compared with a loss of $230.0 million in the fourth quarter of 2024, which included about $341.3 million of impairment charges on unconsolidated joint ventures. Diluted FFO per share fell to $1.64 from $1.79, and the company also issued guidance for the second quarter and full year 2025, with full-year diluted EPS projected at $1.60 to $1.72 and FFO per share at $6.80 to $6.92.

  • Q1 2025 revenue was $865.2 million, up from $858.6 million in Q4 2024.
  • Net income attributable to BXP was $61.2 million ($0.39 per diluted share), versus a loss of $230.0 million ($1.45 per share) in Q4 2024.
  • Diluted FFO per share was $1.64, down from $1.79 in Q4 2024; in-service occupancy was 86.9%, versus 87.5%.
  • Guidance: Q2 2025 diluted EPS of $0.38 to $0.40 and FFO of $1.65 to $1.67 per share; full-year 2025 EPS of $1.60 to $1.72 and FFO of $6.80 to $6.92 per share.
Read the filing on SEC.gov ↗
Apr 22, 5:39 PM ET

BXP amends credit agreement, removing 10 basis point SOFR adjustment on $700.0 million loans

Neutral financing Written later 1.012.03

BXP's operating partnership signed a First Amendment to its Tenth Amended and Restated Credit Agreement with Bank of America, N.A. as administrative agent. The amendment removes a 10 basis point SOFR conversion adjustment that applied to Closing Date Term Loans, on which the company had $700.0 million of principal outstanding. The filing states that other material terms of the credit agreement are unchanged, so the change is administrative in nature for shareholders.

  • Amendment dated April 22, 2025, to the Tenth Amended and Restated Credit Agreement dated March 28, 2025
  • Removes a 10 basis point SOFR conversion adjustment on Closing Date Term Loans
  • Company had $700.0 million in principal outstanding on those loans as of the amendment date
  • All other material terms of the credit agreement remain unchanged
Read the filing on SEC.gov ↗
Mar 31, 7:15 AM ET

BXP amends credit facility to $2.95 billion, extends revolver to 2030

Neutral financing Written later 1.012.038.01

BXP's operating partnership amended and restated its credit agreement on March 28, 2025, lifting the revolving commitment from $2.0 billion to $2.250 billion, extending its maturity to March 29, 2030, and adding a $700.0 million term loan that repaid an earlier $700.0 million term loan due May 2025. The changes lengthen the company's borrowing runway and extend the commercial paper backstop, though the filing also records $300.0 million drawn on the revolver after closing.

  • Total borrowing capacity under the 2025 Credit Facility is up to $2.950 billion, with an option to increase to $3.5 billion subject to syndication
  • Revolving Facility commitment rose from $2.0 billion to $2.250 billion and matures March 29, 2030
  • $300.0 million outstanding under the Revolving Facility after closing
  • Commercial paper program limit raised by $250.0 million to $750.0 million
Read the filing on SEC.gov ↗
Jan 28, 4:38 PM ET

BXP swings to $230.0 million Q4 loss on $341.3 million joint venture impairment

Mixed earnings Written later 2.02

BXP, Inc. reported a fourth-quarter 2024 net loss attributable to BXP of $230.0 million, or $1.45 per diluted share, compared with net income of $83.6 million, or $0.53 per share, in the prior quarter. The loss reflects impairment charges of about $341.3 million on investments in three unconsolidated joint ventures, while diluted FFO per share declined slightly to $1.79 from $1.81. Shareholders should note the impairment-driven loss and the 2025 guidance of $6.77 to $6.95 in diluted FFO per share.

  • Q4 2024 net loss attributable to BXP, Inc. of $230.0 million, or $1.45 per diluted share, versus $0.53 per share in Q3 2024
  • Impairment charges of about $341.3 million related to three unconsolidated joint ventures
  • Q4 2024 total revenue of $858.6 million versus $859.2 million in Q3 2024; diluted FFO per share of $1.79 versus $1.81
  • 2025 guidance: full-year diluted FFO per share of $6.77 to $6.95 and first-quarter 2025 diluted FFO per share of $1.63 to $1.65
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BXP filing is on SEC EDGAR ↗. 8-K briefs of other companies →